Monitor upcoming H2 2026 catalysts: brepocitinib DM launch (end of September), NIU Phase 3 topline data, PH-ILD Phase 2 data, and CLE proof-of-concept data. The Moderna settlement cash ($950M received) provides a strong balance sheet cushion, but the stock remains a binary event-driven play on pipeline readouts rather than financial performance.
Price Chart
Executive Summary
Roivant reported Q1 FY2026 results with a net loss of $0.26 per share, slightly narrower than the $0.33 loss in the prior-year quarter, but the company remains pre-revenue with only $1.4M in revenue. The filing is a routine quarterly update with no material financial surprises; key pipeline catalysts (brepocitinib DM launch, NIU/PH-ILD/CLE readouts) remain on track for H2 2026, and the company repurchased $208.7M in shares. The $950M Moderna settlement payment was received in July, strengthening the balance sheet, but the stock's move will depend on upcoming clinical data rather than these financial results.
Key Financial Metrics
Key Facts
- Net loss per share improved to $0.26 from $0.33 YoY
- Revenue was $1.4M vs $2.2M in the prior-year quarter
- Cash, equivalents, restricted cash and marketable securities of $3.9B as of June 30, 2026 (excluding July Moderna payment)
- Repurchased 7.3M common shares for ~$208.7M during the quarter
- Brepocitinib DM launch on track for end of September 2026; NIU Phase 3 data expected H2 2026
- Genevant received $950M from Moderna in July 2026; additional $1.3B contingent on Section 1498 appeal
- New international lawsuits filed against Pfizer/BioNTech covering 21 jurisdictions
Financial Impact
Net loss of $290.6M in Q1 FY2026 vs $273.9M in Q1 FY2025; operating cash burn continues with R&D expenses rising 32% YoY to $202M
Risk Factors
- Brepocitinib DM launch may underperform expectations
- Clinical trial failures in NIU, PH-ILD, or CLE could significantly impact valuation
- Pfizer/BioNTech litigation outcome uncertain; contingent $1.3B Moderna payment may not materialize
- Cash burn rate increasing with R&D expenses up 32% YoY
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001635088-26-000088 |
| Document: 0001635088-26-000088-index-headers.html | 0001635088-26-000088 |
| Document: 0001635088-26-000088-index.html | 0001635088-26-000088 |
| Document: 0001635088-26-000088.txt | 0001635088-26-000088 |
| 8-K Data (Synthetic) | 0001635088-26-000088 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $36.80 | awaiting T+20 | — | $36.05 (−2.04%) |
Oct 5, 2026 21d ago | Insider Cluster | $35.53 | awaiting T+20 | — | $36.05 (−1.46%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 1, 2026 7w ago | Insider Cluster | $34.18 $36.57 | ▲ +6.99% | ▲ +7.32% | $36.05 (+5.47%) |
Aug 27, 2026 8w ago | Press Release | $37.58 $36.13 | ▼ −3.86% | ▼ −3.35% | $36.05 (−4.07%) |
Aug 27, 2026 8w ago | Press Release | $37.58 $36.13 | ▼ −3.86% | ▼ −3.35% | $36.05 (−4.07%) |
Aug 26, 2026 8w ago | Press Release | $36.75 $38.99 | ▲ +6.10% | ▲ +4.89% | $36.05 (−1.90%) |
Aug 6, 2026 11w ago | 8-K | $35.12 $34.41 | ▼ −2.02% | ▼ −2.62% | $36.05 (+2.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers